Európska únia - slovenčina - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidacloprid, moxidectin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). veterinárny liek môže byť použitý ako súčasť stratégie liečby blechy alergickej dermatitídy (fad).  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). veterinárny liek môže byť použitý ako súčasť stratégie liečby blechy alergickej dermatitídy (fad).

Európska únia - slovenčina - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - antiparazitárne prípravky, insekticídy a repelenty - dogs; cats; ferrets - dogsfor psov, ktorí trpia, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),liečbu hryzenie vší (trichodectes canis),ošetrenie uší roztoč napadnutia (otodectes cynotis), sarcoptic mange (spôsobené sarcoptes scabiei var. canis), demodicosis (spôsobené demodex canis),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis),na liečbu obehového microfilariae (dirofilaria immitis),pri liečbe kožných dirofilariosis (pre dospelých štádií dirofilaria serenoa), na prevenciu kožných dirofilariosis (larvy l3 z dirofilaria serenoa),zníženie obehu microfilariae (dirofilaria serenoa),prevenciu angiostrongylosis (larvy l4 a nezrelé dospelých angiostrongylus vasorum),liečbu angiostrongylus vasorum a crenosoma vulpis,prevencia spirocercosis (spirocerca lupi),liečbu eucoleus (syn. capillaria) boehmi (dospelí),ošetrenie očí červ thelazia callipaeda (dospelí),na liečbu infekcie s gastrointestinálnymi háďatká (larvy l4, nezrelé dospelých a dospelých toxocara canis, ancylostoma caninum a uncinaria stenocephala, dospelí toxascaris leonina a trichuris vulpis). výrobok sa môže používať ako súčasť stratégie liečby pre velká alergie dermatitída (fad). catsfor mačky trpiace, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),ošetrenie uší roztoč napadnutia (otodectes cynotis),liečbu notoedric mange (notoedres cati),spracovanie lungworm eucoleus aerophilus (syn. capillaria aerophila) (dospelí),prevenciu lungworm ochorenia (l3/l4 lariev z aelurostrongylus abstrusus),spracovanie lungworm aelurostrongylus abstrusus (dospelí),čistenie očí červ thelazia callipaeda (dospelí),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis),pri liečbe infekcií s gastrointestinálnymi háďatká (larvy l4, nezrelé dospelých a dospelých toxocara cati a ancylostoma tubaeforme). výrobok sa môže používať ako súčasť stratégie liečby pre velká alergie dermatitída (fad). ferretsfor fretky, ktorí trpia, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis).

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ratiopharm gmbh, nemecko - tiklopidín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaswiss Česká republika s.r.o., Česká republika - tiklopidín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Európska únia - slovenčina - EMA (European Medicines Agency)

univar solutions bv - trientine dihydrochloride - hepatolentikulárna degenerácia - iné alimentárny trakt a metabolizmus výrobky, - cufence je indikovaný na liečbu wilsonova choroba u pacientov netolerantné d-penicilamín terapia, u dospelých a detí vo veku 5 rokov alebo starší.

Európska únia - slovenčina - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotické činidlá - xarelto, spoločne spravované s acetylsalicylová (asa) sám alebo s asa plus klopidogrel alebo ticlopidine, je indikovaný na prevenciu atherothrombotic udalosti v dospelých pacientov po akútnej koronárnej syndróm (acs) so zvýšenou srdcovou biomarkery. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencia žilovej tromboembólie (vte) u dospelých pacientov, ktorí podstúpili operáciu elek- tívneho výmeny bedrového alebo kolenného kĺbu. liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotické činidlá - prevencia žilovej tromboembólie (vte) u dospelých pacientov, ktorí podstúpili operáciu elek- tívneho výmeny bedrového alebo kolenného kĺbu. liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých. (see section 4. 4 for haemodynamically unstable pe patients. liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých. (see section 4. 4 pre haemodynamically nestabilná pe pacientov). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 a 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liečba hlbokej žilovej trombózy (dvt) a pľúcna embólia (pe), a prevencia opakujúcich sa dvt a pe u dospelých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Európska únia - slovenčina - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotické činidlá - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medreg s.r.o., Česká republika - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)